top of page

Congratulations to Dr. Susanne Petri and her team!

NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the CX3ClL1/CX3CR1 Axis Mediated by hMSCs in an Early In Vitro SOD1G93A Model of ALS. The paper was published in November in Biomedicines 2022 and examines the effects of human mesenchymal stem/stromal cell (hMSC)-based therapy on motor neuron survival. This work provides important information in in vitro analysis of the effects of human mesenchymal stem/stromal cell-based therapy on motor neuron survival and the effects on gene expression of growth factors and cytokines/chemokines in motor neurons and hMSCs. They report a higher viability with motor neuron co-culture but no significant protection against STS-induced apoptosis. The authors concluded that there are potential limitations of the therapeutic efficacy of hMSCs in ALS due to cellular crosstalk resulting in increased pro-inflammatory rather than anti-inflammatory signaling. NDR is pleased to provide partial funding for this project.

24 views0 comments

Recent Posts

See All

TVALA Drug Trial

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study will wrap up in a few months and the Phase 2 will start, it will

Thymosin in the treatment of lung cancer

A new paper authored by Liu and Lu in the Frontiers in Immunology reports the Mechanism and clinical application of thymosin in the treatment of lung cancer. Thymosin is a mixture of peptides obtained


We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first paper is by Maor-Nof et. al. (2022), found in Cell. The found


Commenting has been turned off.
bottom of page